109881-25-6

Basic information

• Product Name: 2,6-diaminopurine 2',3'-didehydro-2',3'-dideoxyriboside
• Synonyms: 2,6-diaminopurine 2',3'-didehydro-2',3'-dideoxyriboside;2-Amino-2',3'-didehydro-2',3'-dideoxyadenosine;9-[[(2R,5S)-2,5-Dihydro-5-(hydroxymethyl)furan]-2-yl]-9H-purine-2,6-diamine
• CAS NO: 109881-25-6
• Molecular Formula: C10H12N6O2
• Molecular Weight: 248.24128
• Mol File: 109881-25-6.mol

Chemical Properties

• Boiling Point: 674.3°Cat760mmHg
• Flash Point: 361.6°C
• Appearance: /
• Density: 1.9g/cm³
• CAS DataBase Reference: 2,6-diaminopurine 2',3'-didehydro-2',3'-dideoxyriboside(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-diaminopurine 2',3'-didehydro-2',3'-dideoxyriboside(109881-25-6)
• EPA Substance Registry System: 2,6-diaminopurine 2',3'-didehydro-2',3'-dideoxyriboside(109881-25-6)

Safety Data

• Hazardous Substances Data: 109881-25-6(Hazardous Substances Data)

Usage

Uses

Used in Antiviral Applications:
2,6-Diaminopurine 2',3'-didehydro-2',3'-dideoxyriboside is used as an antiviral agent for its ability to disrupt the synthesis of viral DNA and RNA, showing promise in studies involving HIV and other retroviruses. It serves to inhibit viral replication, offering a potential therapeutic approach against these infections.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 2,6-diaminopurine 2',3'-didehydro-2',3'-dideoxyriboside is used as a research compound to explore its potential in the development of new antiviral and anticancer drugs. Its mechanism of action and effects on various types of viruses and cancer cells are under investigation to determine its suitability for clinical applications.
Used in Cancer Therapy Research:
2,6-Diaminopurine 2',3'-didehydro-2',3'-dideoxyriboside is also being studied for its potential as a therapeutic agent for certain types of cancer. 2,6-diaminopurine 2',3'-didehydro-2',3'-dideoxyriboside's impact on cancer cells and its possible role in cancer treatment are areas of active research, with the aim of identifying new strategies for combating cancer.
Further research is ongoing to fully understand the compound's mechanisms and to explore its potential applications in medicine and drug development, indicating a broad scope for its use across various medical and scientific fields.

Upstream product

• 40635-67-4 acetoxyisobutyryl bromide 
• 2096-10-8 adenosine-2-amine 
• 141684-95-9 2-amino-6-chloro-9-(2,3-dideoxy-β-D-glycero-pent-enofuranosyl)-9H-purine 
• 2004-07-1 2-Amino-6-chloropurine riboside 
• 413570-54-4 9-[5-(tert-butyl-dimethyl-silanyloxymethyl)-2,5-dihydro-furan-2-yl]-6-chloro-9H-purin-2-ylamine 
• 413570-52-2 2-amino-9-(5-O-tert-butyldimethylsilyl-2,3-O-thiocarbonyl-β-D-ribofuranosyl)-6-chloropurine 
• 413570-50-0 2-amino-9-(5-O-tert-butyldimethylsilyl-β-D-ribofuranosyl)-6-chloropurine 

Downstream Products

• 107550-73-2 2,6-diaminopurine 2',3'-dideoxyriboside 

Relevant articles and documents

Nucleic acid related compounds. 114. Synthesis of 2,6-(disubstituted)purine 2′,3′-dideoxynucleosides and selected cytotoxic, anti-hepatitis B, and adenosine deaminase substrate activities

Selected 2,6-(disubstituted)purine 2′,3′-didehydro-2′,3′-dideoxynucleosides and 2′,3′-dideoxynucleosides were prepared and evaluated. Treatment of 5′-protected ribonucleosides with phenoxythiocarbonyl chloride and 4-(dimethylamino)pyridine, or under Schot

Nucleic Acid Related Compounds. 88. Efficient Conversions of Ribonucleosides into Their 2',3'-Anhydro, 2'(and 3')-Deoxy, 2',3'-Didehydro-2',3'-dideoxy, and 2',3'-Dideoxynucleoside Analogues

Treatment of purine, pyrimidine, and modified purine (antibiotic) ribonucleosides with 2-acetoxy-2-methylpropanoyl (α-acetoxyisobutyryl) bromide in acetonitrile gave mixtures of 2',3'-bromohydrin acetates with different O5' substituents.Significant amounts of 5'-unprotected (hydroxyl) bromo acetates were obtained in some cases, and formation of 2',3'-O-isopropylidene derivatives as minor byproducts was detected for the first time.Acid-catalyzed nucleophilic displacement of chloride by bromide occurred with 2-amino-6-chloropurine riboside, but no substitution of fluoride by bromide was detected with 6-amino- 2-fluoropurine riboside.Treatment of the trans bromo acetate mixtures obtained from purine-type nucleosides with Dowex 1 x 2 (OH(-)) in methanol gave the 2',3'-anhydro (ribo epoxide) compounds.Radical-mediated hydrogenolytic debromination and deprotection gave 2'- and 3'-deoxynucleosides.Treatment of the bromo acetate mixtures with zinc-copper couple or acetic acid-activated zinc effected reductive elimination, and deprotection gave 2',3'-didehydro-2',3'-dideoxy compounds which were hydrogenated to give 2',3'-dideoxynucleosides.A number of these analogues have potent inhibitory activity against AIDS and hepatitis B viruses.New 13C NMR data for several types of unsaturated-sugar nucleosides are tabulated.These procedures are directly applicable for the preparation of L-didehydro-dideoxy and L-dideoxy nucleoside analogues.